181 related articles for article (PubMed ID: 37190207)
1. FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma.
Tarin M; Némati F; Decaudin D; Canbezdi C; Marande B; Silva L; Derrien H; Jochemsen AG; Gardrat S; Piperno-Neumann S; Rodrigues M; Mariani P; Cassoux N; Stern MH; Roman-Roman S; Alsafadi S
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190207
[TBL] [Abstract][Full Text] [Related]
2. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma.
Carita G; Frisch-Dit-Leitz E; Dahmani A; Raymondie C; Cassoux N; Piperno-Neumann S; Némati F; Laurent C; De Koning L; Halilovic E; Jeay S; Wylie A; Emery C; Roman-Roman S; Schoumacher M; Decaudin D
Oncotarget; 2016 Jun; 7(23):33542-56. PubMed ID: 27507190
[TBL] [Abstract][Full Text] [Related]
4. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of drug combinations identifies co-inhibition of Bcl-2/XL/W and MDM2 as a potential therapy in uveal melanoma.
Decaudin D; Frisch Dit Leitz E; Nemati F; Tarin M; Naguez A; Zerara M; Marande B; Vivet-Noguer R; Halilovic E; Fabre C; Jochemsen A; Roman-Roman S; Alsafadi S
Eur J Cancer; 2020 Feb; 126():93-103. PubMed ID: 31927215
[TBL] [Abstract][Full Text] [Related]
6. Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
Sagoo MS; Harbour JW; Stebbing J; Bowcock AM
Oncogene; 2014 Sep; 33(39):4722-3. PubMed ID: 24413085
[TBL] [Abstract][Full Text] [Related]
7. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
[TBL] [Abstract][Full Text] [Related]
9. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.
Feng X; Arang N; Rigiracciolo DC; Lee JS; Yeerna H; Wang Z; Lubrano S; Kishore A; Pachter JA; König GM; Maggiolini M; Kostenis E; Schlaepfer DD; Tamayo P; Chen Q; Ruppin E; Gutkind JS
Cancer Cell; 2019 Mar; 35(3):457-472.e5. PubMed ID: 30773340
[TBL] [Abstract][Full Text] [Related]
10. PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma.
Park JJ; Hamad SA; Stewart A; Carlino MS; Lim SY; Rizos H
Oncogenesis; 2024 Feb; 13(1):9. PubMed ID: 38418838
[TBL] [Abstract][Full Text] [Related]
11. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.
Arang N; Lubrano S; Rigiracciolo DC; Nachmanson D; Lippman SM; Mali P; Harismendy O; Gutkind JS
J Biol Chem; 2023 Feb; 299(2):102866. PubMed ID: 36596361
[TBL] [Abstract][Full Text] [Related]
12. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
13. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
[TBL] [Abstract][Full Text] [Related]
15. Combined Inhibition of Gα
Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
[TBL] [Abstract][Full Text] [Related]
16. Selumetinib-based therapy in uveal melanoma patient-derived xenografts.
Decaudin D; El Botty R; Diallo B; Massonnet G; Fleury J; Naguez A; Raymondie C; Davies E; Smith A; Wilson J; Howes C; Smith PD; Cassoux N; Piperno-Neumann S; Roman-Roman S; Némati F
Oncotarget; 2018 Apr; 9(31):21674-21686. PubMed ID: 29774094
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
[TBL] [Abstract][Full Text] [Related]
18. YAP/TAZ Activation Drives Uveal Melanoma Initiation and Progression.
Li H; Li Q; Dang K; Ma S; Cotton JL; Yang S; Zhu LJ; Deng AC; Ip YT; Johnson RL; Wu X; Punzo C; Mao J
Cell Rep; 2019 Dec; 29(10):3200-3211.e4. PubMed ID: 31801083
[TBL] [Abstract][Full Text] [Related]
19. The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.
Amirouchene-Angelozzi N; Frisch-Dit-Leitz E; Carita G; Dahmani A; Raymondie C; Liot G; Gentien D; Némati F; Decaudin D; Roman-Roman S; Schoumacher M
Oncotarget; 2016 Apr; 7(17):23633-46. PubMed ID: 26988753
[TBL] [Abstract][Full Text] [Related]
20. Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
Mitsiades N; Chew SA; He B; Riechardt AI; Karadedou T; Kotoula V; Poulaki V
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7248-55. PubMed ID: 21828154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
